Abbvie INC Form 4 insider transactions

Richard Gonzalez, Executive Chairman of AbbVie, exercised stock options and sold shares on July 17, 2024, according to a Form 4 filing with the SEC.

Director Susan E. Quaggin reports acquisition of AbbVie stock equivalent units as part of director fees.

Director Edward J. Rapp reports acquisition of stock equivalent units and updates to beneficial ownership in AbbVie Inc.

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

AbbVie's CEO, Richard Gonzalez, reported a gift of 6,000 common stock shares on June 28, 2024, leaving him with 513,099 shares.

Director Jennifer L. Davis reports acquisition of 1,322 restricted stock units in AbbVie Inc. on May 3, 2024.

Director Susan E. Quaggin reports acquiring 1,322 shares of AbbVie common stock on May 3, 2024, through restricted stock units.

Director Edward J. Rapp reports acquisition of restricted stock units and indirect ownership through spouse's trust.

Director Robert J. Alpern reports acquisition and disposal of AbbVie common stock and restricted stock units.

Director Thomas C. Freyman reports acquisition and disposal of AbbVie shares, including restricted stock units and shares held in trust.

Director Brett J. Hart reports acquisition of restricted stock units and disposal of common stock in AbbVie Inc.

Director Roxanne S. Austin reports acquisition of restricted stock units and disposal of common stock.

Director Melody B. Meyer reports acquiring restricted stock units and disposing of common stock in AbbVie Inc.

Director Rebecca B. Roberts reports acquisition of restricted stock units and disposition of common stock in AbbVie Inc.

Director William H.L. Burnside reports acquisition and disposal of AbbVie common stock and restricted stock units.

Director Glenn F. Tilton reports acquisition of restricted stock units and disposition of common stock.

Director Frederick H. Waddell reports acquisition of restricted stock units and disposal of common stock in AbbVie Inc.

Director Susan E. Quaggin reports acquisition of AbbVie stock equivalent units through director fees and dividend reinvestment.

Director Robert J. Alpern reports acquisition of stock equivalent units and updates to beneficial ownership in AbbVie Inc.

Director Edward J. Rapp reports acquisition of AbbVie stock equivalent units through director fees credited to a grantor trust.

EVP, Chief Business and Strategy Officer of AbbVie, Nicholas Donoghoe, sold 21,082 shares of common stock at an average price of $176.30 on March 20, 2024.

EVP and Chief Commercial Officer of AbbVie, Jeffrey R. Stewart, reports the sale of AbbVie shares and exercise of stock options on March 18, 2024.

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports exercising stock options and selling shares of common stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

AbbVie's CFO, Scott Reents, exercised stock options and sold shares of common stock on February 23, 2024, according to a Form 4 filing with the SEC.

AbbVie's SVP, Controller Kevin K. Buckbee, reported the sale of 5,144 shares and a transfer of 1,745 shares due to a domestic relations order.

Robert A. Michael, AbbVie's President & Chief Operating Officer, reported multiple transactions involving AbbVie common stock, including sales and option exercises, according to a recent SEC filing.

EVP, GC AND SECRETARY of AbbVie, Perry C. Siatis, reports selling shares of AbbVie stock on February 28 and 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

EVP, Chief Commercial Officer of AbbVie, Jeffrey R. Stewart, reports disposition of shares to cover tax obligations.

Azita Saleki-Gerhardt, EVP and Chief Operations Officer of AbbVie Inc., reported disposing of 23,966 shares of common stock on February 28, 2024, at a price of $178.99 per share.

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports disposing of shares to cover tax obligations.